Patent Application
20150024962
The Sequence Listing associated with this application is filed in electronic format via EFS-Web and hereby incorporated by reference into the specification in its entirety. The name of the text file containing the Sequence Listing is Sequence_Listing—14462—00014_US.txt. The size of the text file is 1, 643 KB, and the text file was created on Aug. 6, 2014.
The present invention relates to new marker sequences for multiple sclerosis and the diagnostic use thereof together with a method for screening potential active substances for multiple sclerosis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing marker sequences of this type for multiple sclerosis, in particular a protein biochip and the use thereof.
Protein biochips are gaining increasing industrial importance in analysis and diagnosis as well as in pharmaceutical development. Protein biochips have become established as screening instruments.
The rapid and highly parallel detection of a multiplicity of specifically binding analysis molecules in a single experiment is rendered possible hereby. To produce protein biochips, it is necessary to have the required proteins available. For this purpose, in particular protein expression libraries have become established. The high throughput cloning of defined open reading frames is one possibility (Heyman, J. A., Cornthwaite, J., Foncerrada, L., Gilmore, J. R., Gontang, E., Hartman, K. J., Hernandez, C. L., Hood, R., Hull, H. M., Lee, W. Y., Marcil, R., Marsh, E. J., Mudd, K. M., Patino, M. J., Purcell, T. J., Rowland, J. J., Sindici, M. L. and Hoeffler, J. P., (1999) Genome-scale cloning and expression of individual open reading frames using topoisomerase I-mediated ligation. Genome Res, 9, 383-392; Kersten, B., Feilner, T., Kramer, A., Wehrmeyer, S., Possling, A., Witt, I., Zanor, M. I., Stracke, R., Lueking, A., Kreutzberger, J., Lehrach, H. and Cahill, D. J. (2003) Generation of Arabidopsis protein chip for antibody and serum screening. Plant Molecular Biology, 52, 999-1010; Reboul, J., Reboul, J., Vaglio, P., Rual, J. F., Lamesch, P., Martinez, M., Armstrong, C. M., Li, S., Jacotot, L., Bertin, N., Janky, R., Moore, T., Hudson, J. R., Jr., Hartley, J. L., Brasch, M. A., Vandenhaute, J., Boulton, S., Endress, G. A., Jenna, S., Chevet, E., Papasotiropoulos, V., Tolias, P. P., Ptacek, J., Snyder, M., Huang, R., Chance, M. R., Lee, H., Doucette-Stamm, L., Hill, D. E. and Vidal, M. (2003) C. elegans ORFeome Version 1.1: experimental verification of the genome annotation and resource for proteome-scale protein expression. Nat Genet, 34, 35-41.; Walhout, A. J., Temple, G. F., Brasch, M. A., Hartley, J. L., Lorson, M. A., van den Heuvel, S. and Vidal, M. (2000) GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol, 328, 575-592). However, an approach of this type is strongly connected to the progress of the genome sequencing projects and the annotation of these gene sequences. Furthermore, the determination of the expressed sequence can be ambiguous due to differential splicing processes. This problem may be circumvented by the application of cDNA expression libraries (Büissow, K., Cahill, D., Nietfeld, W., Bancroft, D., Scherzinger, E., Lehrach, H. and Walter, G. (1998) A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library. Nucleic Acids Research, 26, 5007-5008; Büssow, K., Nordhoff, E., Lübbert, C, Lehrach, H. and Walter, G. (2000) A human cDNA library for high-throughput protein expression screening. Genomics, 65, 1-8; Holz, C, Lueking, A., Bovekamp, L., Gutjahr, C, Bolotina, N., Lehrach, H. and Cahill, D. J. (2001) A human cDNA expression library in yeast enriched for open reading frames. Genome Res, 11, 1730-1735; Lueking, A., Holz, C, Gotthold, C, Lehrach, H. and Cahill, D. (2000) A system for dual protein expression in Pichia pastoris and Escherichia coli, Protein Expr. Purif, 20, 372-378). The cDNA of a particular tissue is hereby cloned into a bacterial or an eukaryotic expression vector, such as, e.g., yeast. The vectors used for the expression are generally characterized in that they carry inducible promoters that may be used to control the time of protein expression. Furthermore, expression vectors have sequences for so-called affinity epitopes or affinity proteins, which on the one hand permit the specific detection of the recombinant fusion proteins by means of an antibody directed against the affinity epitope, and on the other hand the specific purification via affinity chromatography (IMAC) is rendered possible.
For example, the gene products of a cDNA expression library from human fetal brain tissue in the bacterial expression system Escherichia coli were arranged in high-density format on a membrane and could be successfully screened with different antibodies. It was possible to show that the proportion of full-length proteins is at least 66%. Additionally, the recombinant proteins from the library could be expressed and purified in a high-throughput manner (Braun P., Hu, Y., Shen, B., Halleck, A., Koundinya, M., Harlow, E. and LaBaer, J. (2002) Proteome-scale purification of human proteins from bacteria. Proc Natl Acad Sci USA, 99, 2654-2659; Büssow (2000) supra; Lueking, A., Horn, M., Eickhoff, H., Büssow, K., Lehrach, H. and Walter, G. (1999) Protein microarrays for gene expression and antibody screening. Analytical Biochemistry, 270, 103-111). Protein biochips of this type based on cDNA expression libraries are in particular the subject matter of WO 99/57311 and WO 99/57312.
Furthermore, in addition to antigen-presenting protein biochips, antibody-presenting arrangements are likewise described (Lal et al (2002) Antibody arrays: An embryonic but rapidly growing technology, DDT, 7, 143-149; Kusnezow et al. (2003), Antibody microarrays: An evaluation of production parameters, Proteomics, 3, 254-264).
However, there is a great need to provide indication-specific diagnostic devices, such as a protein biochip.
Marker sequences and the diagnostic use thereof for multiple sclerosis, in particular in the embodiment of a protein biochip, as well as tests in this regard for the screening of active substances have not been described in the prior art.
The object of the present invention is therefore to provide marker sequences and their diagnostic use.
The provision of specific marker sequences permits a reliable diagnosis and stratification of patients with multiple sclerosis, in particular by means of a protein biochip.
The invention therefore relates to the use of marker sequences for the diagnosis of multiple sclerosis, wherein at least one marker sequence of a cDNA selected from the group SEQ 1-395 or respectively a protein coding therefor or respectively a partial sequence or fragment thereof (hereinafter: marker sequences according to the invention) is determined on or from a patient to be examined.
It was possible to identify the marker sequences according to the invention by means of differential screening of samples from healthy test subjects with patient samples with multiple sclerosis.
The term “multiple sclerosis (MS), also encephalomyelitis disseminata)” is defined, e.g., according to Pschyrembel, de Gruyter, 261st edition (2007), Berlin and relates to an autoimmune inflammatory/demyelinating and degenerative disorder of the central nervous system.
In a further embodiment at least 2 to 5 or 10, preferably 30 to 50 marker sequences or 50 to 100 or more marker sequences are determined on or from a patient to be examined.
In a particular embodiment of the invention, the marker sequences of the SEQ 1-20 are particularly preferred, the marker sequences SEQ 21-50 are preferred, and furthermore the marker sequences SEQ 51-100 are preferred.
In a further embodiment of the invention, the marker sequences SEQ 1-10 and SEQ 11-20, as well as preferably SEQ 21-30, SEQ 31-40 or SEQ 41-50 are respectively particularly preferred.
In a further embodiment of the invention, the marker sequences according to the invention can likewise be combined, supplemented, fused or expanded likewise with known biomarkers for this indication.
In a preferred embodiment, the determination of the marker sequences is carried out outside the human body and the determination is carried out in an ex vivo/in vitro diagnosis.
In a further embodiment of the invention, the invention relates to the use of marker sequences as diagnostic agents, wherein at least one marker sequence of a cDNA is selected from the group SEQ 1-395 or respectively a protein coding therefor or respectively a partial sequence or fragment thereof.
Furthermore, the invention relates to a method for the diagnosis of multiple sclerosis, wherein a.) at least one marker sequence of a cDNA selected from the group SEQ 1-395 or respectively a protein coding therefor or respectively a partial sequence or fragment thereof is applied to a solid support and b.) is brought into contact with body fluid or tissue extract of a patient and c.) the detection of an interaction of the body fluid or tissue extract with the marker sequences from a.) is carried out.
The invention therefore likewise relates to diagnostic agents for the diagnosis of multiple sclerosis respectively selected from the group SEQ 1-395 or respectively a protein coding therefor or respectively a partial sequence or fragment thereof.
The detection of an interaction of this type can be carried out, for example, by a probe, in particular by an antibody.
The invention therefore likewise relates to the object of providing a diagnostic device or an assay, in particular a protein biochip, which permits a diagnosis or examination for multiple sclerosis.
Furthermore, the invention relates to a method for the stratification, in particular risk stratification and/or therapy control of a patient with multiple sclerosis, wherein at least one marker sequence of a cDNA selected from the group SEQ 1-395 or respectively a protein coding therefor is determined on a patient to be examined.
Furthermore, the stratification of the patients with multiple sclerosis in new or established subgroups of multiple sclerosis is also covered, as well as the expedient selection of patient groups for the clinical development of new therapeutic agents. The term therapy control likewise covers the allocation of patients to responders and non-responders regarding a therapy or the therapy course thereof.
“Diagnosis” for the purposes of this invention means the positive determination of multiple sclerosis by means of the marker sequences according to the invention as well as the assignment of the patients to multiple sclerosis. The term diagnosis covers medical diagnostics and examinations in this regard, in particular in-vitro diagnostics and laboratory diagnostics, likewise proteomics and nucleic acid blotting. Further tests can be necessary to be sure and to exclude other diseases. The term diagnosis therefore likewise covers the differential diagnosis of multiple sclerosis by means of the marker sequences according to the invention and the prognosis of multiple sclerosis.
“Stratification or therapy control” for the purposes of this invention means that the method according to the invention renders possible decisions for the treatment and therapy of the patient, whether it is the hospitalization of the patient, the use, effect and/or dosage of one or more drugs, a therapeutic measure or the monitoring of a course of the disease and the course of therapy or etiology or classification of a disease, e.g., into a new or existing subtype or the differentiation of diseases and the patients thereof.
In a further embodiment of the invention, the term “stratification” covers in particular the risk stratification with the prognosis of an outcome of a negative health event.
Within the scope of this invention, “patient” means any test subject—human or mammal—with the proviso that the test subject is tested for multiple sclerosis.
The term “marker sequences” for the purposes of this invention means that the cDNA or the polypeptide or protein that can be respectively obtained therefrom are significant for multiple sclerosis. For example, the cDNA or the polypeptide or protein that can be respectively obtained therefrom can exhibit an interaction with substances from the body fluid or tissue extract of a patient with multiple sclerosis (e.g., antigen (epitope)/antibody (paratope) interaction). For the purposes of the invention “wherein at least one marker sequence of a cDNA selected from the group SEQ 1-395 or respectively a protein coding therefor or respectively a partial sequence or fragment thereof is determined on a patient to be examined” means that an interaction between the body fluid or tissue extract of a patient and the marker sequences according to the invention is detected. An interaction of this type is, e.g., a bond, in particular a binding substance on at least one marker sequence according to the invention or in the case of a cDNA the hybridization with a suitable substance under selected conditions, in particular stringent conditions (e.g., such as usually defined in J. Sambrook, E. F. Fritsch, T. Maniatis (1989), Molecular cloning: A laboratory manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA or Ausubel, “Current Protocols in Molecular Biology,” Green Publishing Associates and Wiley Interscience, N. Y. (1989)). One example of stringent hybridization conditions is: hybridization in 4×SSC at 65° C. (alternatively in 50% formamide and 4×SSC at 42° C.), followed by several washing steps in 0.1×SSC at 65° C. for a total of approximately one hour. An example of less stringent hybridization conditions is hybridization in 4×SSC at 37° C., followed by several washing steps in 1×SSC at room temperature.
According to the invention, substances of this type are constituents of a body fluid, in particular blood, whole blood, blood plasma, blood serum, patient serum, urine, cerebrospinal fluid, synovial fluid or of a tissue extract of the patient.
In a further embodiment of the invention, however, the marker sequences according to the invention can be present in a significantly higher or lower expression rate or concentration that indicates multiple sclerosis. The relative sick/healthy expression rates of the marker sequences for multiple sclerosis according to the invention are hereby determined by means of proteomics or nucleic acid blotting.
In a further embodiment of the invention, the marker sequences have a recognition signal that is addressed to the substance to be bound (e.g., antibody, nucleic acid). It is preferred according to the invention for a protein the recognition signal is an epitope and/or a paratope and/or a hapten and for a cDNA is a hybridization or binding region.
The marker sequences according to the invention are the subject matter of Table A and can be clearly identified by the respectively cited database entry (also by means of the Internet: http://www.ncbi.nlm.nih.gov/) (see in Table A: accession no. there).
According to the invention, the marker sequences also cover those modifications of the cDNA sequence and the corresponding amino acid sequence as chemical modification, such as citrullination, acetylation, phosphorylation, glycosylation or poly(A) strand and other modifications known to one skilled in the art.
In a further embodiment of the invention, partial sequences or fragments of the marker sequences according to the invention are likewise covered. In particular those partial sequences that have an identity of 95%, 90%, in particular 80% or 70% with the marker sequences according to the invention.
In a further embodiment, the respective marker sequence can be represented in different quantities in one more regions on a solid support. This permits a variation of the sensitivity. The regions can have respectively a totality of marker sequences, i.e., a sufficient number of different marker sequences, in particular 2 to 5 or 10 or more and optionally more nucleic acids and/or proteins, in particular biomarkers. However, at least 96 to 25,000 (numerical) or more from different or identical marker sequences and further nucleic acids and/or proteins, in particular biomarkers are preferred. Furthermore preferred are more than 2, 5000, in particular preferred 10,000 or more different or identical marker sequences and optionally further nucleic acids and/or proteins, in particular biomarkers.
Another object of the invention relates to an arrangement of marker sequences containing at least one marker sequence of a cDNA selected from the group SEQ 1-395 or respectively a protein coding therefor. Preferably, the arrangement contains at least 2 to 5 or 10, preferably 30 to 50 marker sequences or 50 to 100 or more marker sequences. Within the scope of this invention, “arrangement” is synonymous with “array,” and if this “array” is used to identify substances on marker sequences, this is to be understood to be an “assay” or diagnostic device. In a preferred embodiment, the arrangement is designed such that the marker sequences represented on the arrangement are present in the form of a grid on a solid support. Furthermore, those arrangements are preferred that permit a high-density arrangement of protein binders and the marker sequences are spotted. Such high-density spotted arrangements are disclosed, for example, in WO 99/57311 and WO 99/57312 and can be used advantageously in a robot-supported automated high-throughput method.
Within the scope of this invention, however, the term “assay” or diagnostic device likewise comprises those embodiments of a device, such as ELISA (e.g., individual wells of a microtiter plate are coated with the marker sequences or combinations of marker sequences according to the invention, optionally applied in a robot-supported manner in the individual wells of the microtiter plate; examples are diagnostic ELISA kits by Phadia or “Searchlight” multiplex ELISA kits by Pierce/Thermo Fisher Scientific), bead-based assay (spectrally distinguishable bead populations are coated with marker sequences/combinations of marker sequences. The patient sample is incubated with this bead population and bound (auto) antibodies are detected by means of a further fluorescence-labeled secondary antibody/detection reagent via measurement of the fluorescence; i.e., Borrelia IgG kit or Athena Multilyte by Multimetrix), line assay (marker sequences according to the invention or combinations of marker sequences are immobilized on membranes in a robot-supported manner, which are examined/incubated with the patient sample; example “Euroline” by Euroimmun AG), Western Blot (example “Euroline-WB” by Euroimmun AG), immunochromatographic methods (e.g., lateral flow immunoassays; marker sequences/combinations of marker sequences are immobilized on test strips (membranes, U.S. Pat. No. 5,714,389 and the like); example “One Step HBsAg” test device by Acon Laboratories) or similar immunological single or multiplex detection measures.
The marker sequences of the arrangement are fixed on a solid support, but preferably spotted or immobilized even printed on, i.e. applied in a reproducible manner. One or more marker sequences can be present multiple times in the totality of all marker sequences and present in different quantities based on one spot. Furthermore, the marker sequences can be standardized on the solid support (i.e., by means of serial dilution series of, e.g., human globulins as internal calibrators for data normalization and quantitative evaluation).
The invention therefore relates to an assay or a protein biochip comprising an arrangement containing marker sequences according to the invention.
In a further embodiment, the marker sequences are present as clones. Clones of this type can be obtained, for example, by means of a cDNA expression library according to the invention (Büssow et al. 1998 (supra)). In a preferred embodiment, such expression libraries containing clones are obtained using expression vectors from a cDNA expression library comprising the cDNA marker sequences. These expression vectors preferably contain inducible promoters. The induction of the expression can be carried out, e.g., by means of an inductor, such as IPTG. Suitable expression vectors are described in Terpe et al. (Terpe T Appl Microbiol Biotechnol. 2003 January; 60(5): 523-33).
One skilled in the art is familiar with expression libraries, they can be produced according to standard works, such as Sambrook et al, “Molecular Cloning, A laboratory handbook, 2nd edition (1989), CSH press, Cold Spring Harbor, N.Y. Expression libraries are also preferred which are tissue-specific (e.g., human tissue, in particular human organs). Furthermore included according to the invention are expression libraries that can be obtained by exon-trapping. A synonym for expression library is expression bank.
Also preferred are protein biochips or corresponding expression libraries that do not exhibit any redundancy (so-called: Uniclone® library) and that may be produced, for example, according to the teachings of WO 99/57311 and WO 99/57312. These preferred Uniclone libraries have a high portion of non-defective fully expressed proteins of a cDNA expression library.
Within the context of this invention, the clones can also be, but not limited to, transformed bacteria, recombinant phages or transformed cells from mammals, insects, fungi, yeasts or plants.
The clones are fixed, spotted or immobilized on a solid support.
The invention therefore relates to an arrangement wherein the marker sequences are present as clones.
Additionally, the marker sequences can be present in the respective form of a fusion protein, which contains, for example, at least one affinity epitope or tag. The tag may be one such as contains c-myc, his tag, arg tag, FLAG, alkaline phosphatase, VS tag, T7 tag or strep tag, HAT tag, NusA, S tag, SBP tag, thioredoxin, DsbA, a fusion protein, preferably a cellulose-binding domain, green fluorescent protein, maltose-binding protein, calmodulin-binding protein, glutathione S-transferase or lacZ.
A marker sequence can also be composed of several individual marker sequences. This can comprise the cloning of individual fragments to form a large common fragment and the expression of this combined fragment.
In all of the embodiments, the term “solid support” covers embodiments such as a filter, a membrane, a magnetic or fluorophore-labeled bead, a silica wafer, glass, metal, ceramics, plastics, a chip, a target for mass spectrometry or a matrix. However, a filter is preferred according to the invention.
As a filter, furthermore PVDF, nitrocellulose or nylon is preferred (e.g., Immobilon P Millipore, Protran Whatman, Hybond N+Amersham).
In another preferred embodiment of the arrangement according to the invention, the arrangement corresponds to a grid with the dimensions of a microtiter plate (8-12 wells strips, 96 wells, 384 wells or more), a silica wafer, a chip, a target for mass spectrometry, or a matrix.
In a further embodiment, the invention relates to an assay or a protein biochip for identifying and characterizing a substance for multiple sclerosis, characterized in that an arrangement or assay according to the invention is a.) brought into contact with at least one substance to be tested and b.) a binding success is detected.
Furthermore, the invention relates to a method for identifying and characterizing a substance for multiple sclerosis, characterized in that an arrangement or assay according to the invention is a.) brought into contact with at least one substance to be tested and b.) a binding success is detected.
The substance to be tested can be any native or non-native biomolecule, a synthetic chemical molecule, a mixture or a substance library.
After the substance to be tested contacts a marker sequence, the binding success is evaluated, which, for example, is carried out using commercially available image analyzing software (GenePix Pro (Axon Laboratories), Aida (Ray test), ScanArray (Packard Bioscience).
The visualization of protein-protein interactions according to the invention (e.g., protein on marker sequence, as antigen/antibody) or corresponding “means for detecting the binding success” can be performed, for example, using fluorescence labeling, biotinylation, radioisotope labeling or colloid gold or latex particle labeling in the usual way. A detection of bound antibodies is carried out with the aid of secondary antibodies, which are labeled with commercially available reporter molecules (e.g., Cy, Alexa, Dyomics, FITC or similar fluorescent dyes, colloidal gold or latex particles), or with reporter enzymes, such as alkaline phosphatase, horseradish peroxidase, etc., and the corresponding colorimetric, fluorescent or chemiluminescent substrates. Readout is conducted, e.g., using a microarray laser scanner, a CCD camera or visually.
In a further embodiment, the invention relates to a drug/active substance or prodrug developed for multiple sclerosis and obtainable through the use of the assay or protein biochip according to the invention.
The invention therefore likewise relates to the use of an arrangement according to the invention or an assay for screening active substances for multiple sclerosis.
In a further embodiment, the invention therefore likewise relates to a target for the treatment and therapy of multiple sclerosis respectively selected from the group SEQ 1-395 or a protein respectively coding therefor.
In a further embodiment, the invention likewise relates to the use of the marker sequences according to the invention, preferably in the form of an arrangement, as an affinity material for carrying out an apheresis or in the broadest sense a blood lavage, wherein substances from body fluids of a patient with multiple sclerosis, such as blood or plasma, bind to the marker sequences according to the invention and consequently can be selectively withdrawn from the body fluid.
Ten or more patient samples were individually screened against a cDNA expression library. The multiple sclerosis-specific expression clones were determined through a comparison with ten or more healthy samples. The identity of the marker sequences was determined by DNA sequencing.
Homo sapiens chromosome 9 genomic contig, reference assembly
Homo sapiens CREB binding protein (Rubinstein-Taybi syndrome) (CREBBP), mRNA
Homo sapiens chromosome 16 genomic contig, reference assembly
Homo sapiens B-cell CLL/lymphoma 11A (zinc finger protein) (BCL11A),
Homo sapiens splicing factor, arginine/serine-rich 1 (splicing factor 2,
Homo sapiens proteasome (prosome, macropain) 26S subunit, non-ATPase, 9
Homo sapiens Ras and Rab interactor 3 (RIN3), mRNA
Homo sapiens dihydrouridine synthase 1-like (S. cerevisiae) (DUS1L), mRNA
Homo sapiens zinc finger protein 638 (ZNF638), transcript variant 1, mRNA
Homo sapiens ubiquitin-fold modifier conjugating enzyme 1 (UFC1), mRNA
Homo sapiens STIP1 homology and U-box containing protein 1 (STUB1), mRNA
Homo sapiens interleukin-1 receptor-associated kinase 1 (IRAK1), transcript
Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type I, gamma
Homo sapiens chromosome 16 genomic contig, reference assembly
Homo sapiens nuclear mitotic apparatus protein 1 (NUMA1), mRNA
Homo sapiens chromosome 16 genomic contig, alternate assembly
Homo sapiens similar to KIAA0592 protein (LOC387680), mRNA
Homo sapiens CUE domain containing 2 (CUEDC2), mRNA
Homo sapiens STIP1 homology and U-box containing protein 1 (STUB1), mRNA
Homo sapiens roundabout, axon guidance receptor, homolog 3 (Drosophila)
Homo sapiens chromosome 17 genomic contig, reference assembly
Homo sapiens chromosome 16 genomic contig, alternate assembly
Homo sapiens MYC-associated zinc finger protein
Homo sapiens ubiquitin-binding protein homolog (UBPH), mRNA
Homo sapiens inhibitor of growth family, member 4 (ING4), mRNA
Homo sapiens chromosome 3 open reading frame 19 (C3orf19), mRNA
Homo sapiens pyruvate kinase, muscle (PKM2), transcript variant 3, mRNA
Homo sapiens required for melotic nuclear division 5 homolog B
Homo sapiens chromosome 8 genomic contig, reference assembly
Homo sapiens inhibitor of growth family, member 4 (ING4), mRNA
Homo sapiens inhibitor of growth family, member 4 (ING4), mRNA
Homo sapiens microtubule-associated protein 1 light chain 3 alpha (MAP1LC3A),
Homo sapiens stathmin-like 4 (STMN4), mRNA
Homo sapiens CUE domain containing 2 (CUEDC2), mRNA
Homo sapiens MYC-associated zinc finger protein
Homo sapiens B-cell CLL/lymphoma 11B (zinc finger protein) (BCL11B),
Homo sapiens GRINL1A combined protein (Gcom1), transcript variant 9, mRNA
Homo sapiens polymerase (RNA) I polypeptide D, 16 kDa (POLR1D), transcript
Homo sapiens pleiotrophin (heparin binding growth factor 8, neurite growth-
Homo sapiens chromosome 22 genomic contig, reference assembly
Homo sapiens chromosome 16 genomic contig, reference assembly
Homo sapiens ferritin, heavy polypeptide 1 (FTH1), mRNA
Homo sapiens cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Homo sapiens peroxiredoxin 1 (PRDX1), transcript variant 3, mRNA
Homo sapiens calsyntenin 1 (CLSTN1), transcript variant 2, mRNA
Homo sapiens FK506 binding protein 3, 25 kDa (FKBP3), mRNA
Homo sapiens splicing factor, arginine/serine-rich 4 (SFRS4), mRNA
Homo sapiens similar to KIAA0592 protein (LOC387680), mRNA
Homo sapiens GABA(A) receptor-associated protein (GABARAP), mRNA
Homo sapiens zinc finger protein 133 (ZNF133), mRNA
Homo sapiens zinc finger protein 133 (ZNF133), mRNA
Homo sapiens tubulin tyroslne ligase-like family, member 12 (TTLL12), mRNA
Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type I, gamma (PIP5K1C),
Homo sapiens zinc finger protein 313 (ZNF313), mRNA
Homo sapiens tropomyosin 3 (TPM3), transcript variant 2, mRNA
Homo sapiens CUE domain containing 2 (CUEDC2), mRNA
Homo sapiens CUE domain containing 2 (CUEDC2), mRNA
Homo sapiens nuclear receptor coactivator 5 (NCOA5), mRNA
Homo sapiens ubiquitin-fold modifier conjugating enzyme 1 (UFC1), mRNA
Homo sapiens hairy and enhancer of split 5 (Drosophila) (HES5), mRNA
Homo sapiens methyl-CpG binding domain protein 3 (MBD3), mRNA
Homo sapiens sorcin (SRI), transcript variant 1, mRNA
Homo sapiens leucine rich repeat containing 45 (LRRC45), mRNA
Homo sapiens myosin, light chain 6B, alkali, smooth muscle and non-muscle
Homo sapiens albumin (ALB), mRNA
Homo sapiens cyclic AMP-regulated phosphoprotein, 21 kD (ARPP-21),
Homo sapiens mitochondrial ribosomal protein S11 (MRPS11), nuclear gene encoding
Homo sapiens cytoskeleton associated protein 1 (CKAP1), mRNA
Homo sapiens pyruvate kinase, muscle (PKM2), transcript variant 3, mRNA
Homo sapiens STIP1 homology and U-box containing protein 1 (STUB1), mRNA
Homo sapiens tubulin, beta 3 (TUBB3), mRNA
Homo sapiens stathmin-like 3 (STMN3), mRNA
Homo sapiens tubulin, beta 3 (TUBB3), mRNA
Homo sapiens stomatin (EPB72)-like 2 (STOML2), mRNA
Homo sapiens ring finger protein 130 (RNF130), mRNA
Homo sapiens zinc finger protein 768 (ZNF768), mRNA
Homo sapiens cysteine and glycine-rich protein 2 (CSRP2), mRNA
Homo sapiens kinesin 2 (KNS2), transcript variant 2, mRNA
Homo sapiens myosin, light chain 68, alkali, smooth muscle and non-muscle
Homo sapiens paralemmin (PALM), transcript variant 2, mRNA
Homo sapiens STIP1 homology and U-box containing protein 1 (STUB1), mRNA
Homo sapiens chromosome 15 genomic contig, reference assembly
Homo sapiens zinc finger protein 638 (ZNF638), transcript variant 1, mRNA
Homo sapiens fusion (involved in t(12; 16) in malignant liposarcoma)(FUS)
Homo sapiens ribosomal protein L8 (RPL8)
Homo sapiens heterogeneous nuclear ribonucleoprotein A/B (HNRPAB)
Homo sapiens splicing factor, arginine/serine-rich 10 (SFRS10)
Homo sapiens tropomyosin 3 (TPM3)
omo sapiens hepatoma-derived growth factor (high-mobility group protein 1-like)
Homo sapiens nucleolar protein with MIF4G domain 1 (NOM1)
Homo sapiens myosin, heavy chain 9, non-muscle (MYH9)
Homo sapiens forkhead box E3 (FOXE3)
Homo sapiens KIAA1196 protein (GM632)
Homo sapiens myosin, heavy chain 9, non-muscle (MYH9)
Homo sapiens Ras association (RalGDS/AF-6) domain family 7 (RASSF7)
Homo sapiens polypyrimidine tract binding protein 1 (PTBP1)
Homo sapiens polypyrimidine tract binding protein 1 (PTBP1)
Homo sapiens Y box binding protein 1 (YBX1)
Homo sapiens Y box binding protein 1 (YBX1)
Homo sapiens hepatoma-derived growth factor (high-mobility group protein 1-like)
Homo sapiens Y box binding protein 1 (YBX1)
Homo sapiens nucleolar protein with MIF4G domain 1 (NOM1)
Homo sapiens Y box binding protein 1 (YBX1)
Homo sapiens endoplasmic reticulum protein 29 (ERP29)
Homo sapiens chromosome 6 open reading frame 153 (C6orf153)
Homo sapiens polypyrimidine tract binding protein 1 (PTBP1)
omo sapiens splicing factor, arginine/serine-rich 10 (SFRS10)
Homo sapiens ubiquitin C (UBC)
Homo sapiens Treacher Collins-Franceschetti syndrome 1 (TCOF1)
Homo sapiens hippocalcin like 4 (HPCAL4)
Homo sapiens apolipoprotein B48 receptor (APOB48R)
Homo sapiens Y box binding protein 1 (YBX1)
Homo sapiens cyclin-dependent kinase inhibitor 2D (p19, Inhibits CDK4)
Homo sapiens hepatoma-derived growth factor (high-mobility group protein
Homo sapiens endoplasmic reticulum protein 29 (ERP29)
Homo sapiens ribosomal protein S8 (RPS8)
Homo sapiens CXXC finger 1 (PHD domain) (CXXC1), mRNA
Homo sapiens fusion (involved in t(12; 16) in malignant liposarcoma)
Homo sapiens cold shock domain containing E1, RNA-binding (CSDE1),
Homo sapiens cysteine-rich protein 2 (CRIP2), mRNA
Homo sapiens coiled-coil domain containing 88 (CCDC88), mRNA
Homo sapiens jun oncogene (JUN), mRNA
Homo sapiens jun D proto-oncogene (JUND), mRNA
Homo sapiens B-cell CLL/lymphoma 11B (zinc finger protein) (BCL11B),
Homo sapiens v-abl Abelson murine leukemia viral oncogens homolog 1
Homo sapiens MYC-associated zinc finger protein (purine-binding
Homo sapiens myosin, heavy chain 9, non-muscle (MYH9), mRNA
Homo sapiens ribonuclease III, nuclear (RNASEN), mRNA
Homo sapiens solute carrier family 25 (mitochondrial carrier; adenine
Homo sapiens chromosome 1 genomic contig, reference assembly
Homo sapiens exostoses (multiple) 1 (EXT1), mRNA
Homo sapiens carbohydrate sulfotransferase 10 (CHST10), mRNA
Homo sapiens chromosome 17 genomic contig, alternate assembly
Homo sapiens neurogenic differentiation 2 (NEUROD2), mRNA
Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax
Homo sapiens chromosome X genomic contig, reference assembly
Homo sapiens Fas (TNFRSF6)-associated via death domain (FADD), mRNA
Homo sapiens kelch-like 21 (Drosophila) (KLHL21), mRNA
Homo sapiens homer homolog 3 (Drosophila) (HOMER3), mRNA
Homo sapiens chromosome 12 genomic contig, reference assembly
Homo sapiens protein arginine methyltransferase 1 (PRMT1),
Homo sapiens chromosome 10 open reading frame 58 (C10orf58), mRNA
Homo sapiens coenzyme Q10 homolog A (S. cerevisiae) (COQ10A), mRNA
Homo sapiens p53 and DNA damage regulated 1 (PDRG1), mRNA
Homo sapiens inhibitor of growth family, member 4 (ING4), mRNA
Homo sapiens fatty acid desaturase 3 (FADS3), mRNA
Homo sapiens poliovirus receptor-related 2 (herpesvirus entry mediator B)
Homo sapiens eukaryotic translation initiation factor-4E binding protein 1
Homo sapiens heat shock 105 kDa/110 kDa protein 1 (HSPH1), mRNA
Homo sapiens chromosome 9 genomic contig, reference assembly
Homo sapiens HGFL gene (MGC17330), mRNA
Homo sapiens RAE1 RNA export 1 homolog (S. pombe) (RAE1), transcript
Homo sapiens heterogeneous nuclear ribonucleoprotein A1 (HNRPA1), transcript
Homo sapiens protein phosphatase 1, catalytic subunit alpha isoform (PPP1CA),
Homo sapiens atrophin 1 (ATN1), transcript variant 2, mRNA
Homo sapiens stathmin-like 4 (STMN4), mRNA
Homo sapiens excision repair cross-complementing rodent repair deficiency,
Homo sapiens coactosin-like 1 (Dictyostelium) (COTL1), mRNA
Homo sapiens general transcription factor IIE, polypeptide 2, beta 34 kDa
Homo sapiens coactosin-like 1 (Dictyostelium) (COTL1), mRNA
Homo sapiens 6-phosphogluconolactonase (PGLS), mRNA
Homo sapiens leucine rich repeat containing 47 (LRRC47), mRNA
Homo sapiens pogo transposable element with KRAB domain (POGK), mRNA
Homo sapiens phospholipase C, gamma 1 (PLCG1), transcript variant 1, mRNA
Homo sapiens 6-phosphogluconolactonase (PGLS), mRNA
Homo sapiens triple functional domain (PTPRF interacting) (TRIO), mRNA
Homo sapiens ankyrin repeat and sterile alpha motif domain containing 6
Homo sapiens phospholipase D family, member 3 (PLD3), transcript variant 1, mRNA
Homo sapiens coenzyme Q4 homolog (S. cerevisiae) (COQ4), mRNA
Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type I, gamma
Homo sapiens histone deacetylase 5 (HDAC5), transcript variant 1, mRNA
Homo sapiens phospholipase C, beta 2 (PLCB2), mRNA
Homo sapiens BRCA1 associated protein (BRAP), mRNA
Homo sapiens chromosome 17 genomic contig, reference assembly
Homo sapiens heterogeneous nuclear ribonucleoprotein A0 (HNRPA0), mRNA
Homo sapiens alveolar soft part sarcoma chromosome region, candidate 1
Homo sapiens 6-phosphogluconolactonase (PGLS), mRNA
Homo sapiens lamin B1 (LMNB1), mRNA
Homo sapiens chromosome 22 genomic contig, reference assembly
Homo sapiens histone deacetylase 10 (HDAC10), mRNA
Homo sapiens chromosome 19 genomic contig, alternate assembly
Homo sapiens synaptotagmin V (SYT5), mRNA
Homo sapiens MARCKS-like 1 (MARCKSL1), mRNA
Homo sapiens leucine rich repeat containing 47 (LRRC47), mRNA
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens chromosome 9 genomic contig, reference assembly
Homo sapiens TNF receptor-associated protein 1 (TRAP1), mRNA
Homo sapiens stathmin-like 4 (STMN4), mRNA
Homo sapiens coiled-coil-helix-coiled-coil-helix domain containing 2
Homo sapiens TNF receptor-associated factor 4 (TRAF4), transcript variant 1,
Homo sapiens serine/threonine kinase 25 (STE20 homolog, yeast) (STK25), mRNA
Homo sapiens junction plakoglobin (JUP), transcript variant 2, mRNA
Homo sapiens pleiotrophin (heparin binding-growth factor 8, neurite growth-
Homo sapiens Y box binding protein 1 (YBX1), mRNA
Homo sapiens chromosome 7 genomic contig, reference assembly
Homo sapiens coactosin-like 1 (Dictyostelium) (COTL1), mRNA
Homo sapiens serum response factor (c-fos serum response element-binding
Homo sapiens SWI/SNF related, matrix associated, actin dependent regulator of
Homo sapiens SWI/SNF related, matrix associated, actin dependent regulator of
Homo sapiens selenoprotein O (SELO), mRNA
Homo sapiens zinc finger protein 786 (ZNF788), mRNA
Homo sapiens hypothetical gene supported by BC044942 (LOC441268), mRNA
Homo sapiens ARP1 actin-related protein 1 homolog A, centractin alpha (yeast)
Homo sapiens 3-phosphoinositide dependent protein kinase-1 (PDPK1), transcript
Homo sapiens STAM binding protein-like 1 (STAMBPL1), mRNA
Homo sapiens coactosin-like 1 (Dictyostelium) (COTL1), mRNA
Homo sapiens zinc finger, FYVE domain containing 27 (ZFYVE27), transcript
Homo sapiens chromosome 5 genomic contig, reference assembly
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens mitogen-activated protein kinase 11 (MAPK11), mRNA
Homo sapiens CDC42 binding protein kinase beta (DMPK-like) (CDC42BPB), mRNA
Homo sapiens programmed cell death 7 (PDCD7), mRNA
Homo sapiens nucleotide binding protein 2 (MinD homolog, E. coli) (NUBP2),
Homo sapiens Ts translation elongation factor, mitochondrial (TSFM), mRNA
Homo sapiens septin 9 (SEPT9), mRNA
Homo sapiens amyloid beta (A4) precursor-like protein 1 (APLP1), transcript
Homo sapiens p53 and DNA damage regulated 1 (PDRG1), mRNA
Homo sapiens chromosome 16 genomic contig, alternate assembly
Homo sapiens single stranded DNA binding protein 4 (SSBP4), transcript
Homo sapiens splicing factor, arginine/serine-rich 7, 35 kDa (SFRS7), mRNA
Homo sapiens zinc finger protein 358 (ZNF358), mRNA
Homo sapiens chromosome 1 genomic contig, reference assembly
Homo sapiens phosphoprotein enriched in astrocytes 15 (PEA15), mRNA
Homo sapiens p53 and DNA damage regulated 1 (PDRG1), mRNA
Homo sapiens Y box binding protein 1 (YBX1), mRNA
Homo sapiens Y box binding protein 1 (YBX1), mRNA
Homo sapiens seryl-tRNA synthetase (SARS), mRNA
Homo sapiens inhibitor of growth family, member 4 (ING4), mRNA
Homo sapiens chromosome 10 open reading frame 58 (C10orf58), mRNA
Homo sapiens chromosome 17 genomic contig, alternate assembly
Homo sapiens ubiquitin A-52 residue ribosomal protein fusion product 1
Homo sapiens lamin A/C (LMNA)
Homo sapiens dual specificity phosphatase 2 (DUSP2
Homo sapiens DnaJ (Hsp40) homolog, subfamily C, member 9 (DNAJC9)
Homo sapiens ribosomal protein S27a (RPS27A)
Homo sapiens DnaJ (Hsp40) homolog, subfamily C, member 9 (DNAJC9)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens AFG3 ATPase family gene 3-like 2 (yeast) (AFG3L2)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens myosin, heavy chain 9, non-muscle (MYH9)
Homo sapiens bleomycin hydrolase (BLMH
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens lamin A/C (LMNA), transcript variant 2
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens lamin A/C (LMNA), transcript variant 2
Homo sapiens DnaJ (Hsp40) homolog, subfamily C, member 9 (DNAJC9)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens nuclear factor of kappa light polypeptide gene enhancer
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens ribosomal protein S27a (RPS27A)
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens glioma tumor suppressor candidate region gene 1
Homo sapiens dual specificity phosphatase 2 (DUSP2)
Homo sapiens PCI domain containing 1 (herpesvirus entry mediator) (PCID1)
Homo sapiens histocompatibility (minor) HA-1 (HMHA1)
Homo sapiens ribosomal protein S27a (RPS27A), mRNA
Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA
Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA
Homo sapiens ribosomal protein S27a (RPS27A), mRNA
Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA
Homo sapiens Rho GTPase activating protein 30 (ARHGAP30), transcript
Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA
Homo sapiens myosin, heavy chain 9, non-muscle (MYH9), mRNA
Homo sapiens junctophilin 3 (JPH3), mRNA
Homo sapiens opioid receptor, sigma 1 (OPRS1), transcript variant 3, mRNA
Homo sapiens proteasome (prosome, macropain) 26S subunit, non-ATPase, 3
Homo sapiens solute carrier family 35, member B2 (SLC35B2), mRNA
Homo sapiens discs, large (Drosophila) homolog-associated
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens chromosome 17 genomic contig, reference assembly
Homo sapiens histone deacetylase 5 (HDAC5), transcript variant 1, mRNA
Homo sapiens chromosome 12 genomic contig, reference assembly
Homo sapiens eomesodermin homolog (Xenopus laevis)
Homo sapiens chromosome 2 genomic contig, reference assembly
Homo sapiens mitochondrial ribosomal protein S24 (MRPS24), nuclear gene
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens protein phosphatase 1, regulatory subunit 10 (PPP1R10), mRNA
Homo sapiens MYC-associated zinc finger protein (purine-binding transcription
Homo sapiens F-box and leucine-rich repeat protein 10 (FBXL10), transcript
Homo sapiens solute carrier family 25 (mitochondrial carrier; citrate transporter),
Homo sapiens syntaxin 18 (STX18), mRNA
Homo sapiens glycerol-3-phosphate dehydrogenase 1 (soluble) (GPD1), mRNA
Homo sapiens HMP19 protein (HMP19), mRNA
Homo sapiens tubulin, alpha 3 (TUBA3), mRNA
Homo sapiens chromosome 14 genomic contig, reference assembly
Homo sapiens zinc finger protein 768 (ZNF768), mRNA
Homo sapiens chromosome 4 genomic contig, reference assembly
Homo sapiens calcium channel, voltage-dependent, gamma subunit 4 (CACNG4), mRNA
Homo sapiens synaptogyrin 3 (SYNGR3), mRNA
Homo sapiens hippocalcin like 4 (HPCAL4), mRNA
Homo sapiens capicua homolog (Drosophila) (CIC), mRNA
Homo sapiens tubulin, beta 2A (TUBB2A), mRNA
Homo sapiens fibronectin type III domain containing 4 (FNDC4), mRNA
Homo sapiens dynamin 2 (DNM2), transcript variant 4, mRNA
Homo sapiens sema domain, immunoglobulin domain (Ig), transmembrane domain
Homo sapiens helicase (DNA) B (HELB), mRNA
Homo sapiens GNAS complex locus (GNAS), transcript variant 4, mRNA
Homo sapiens chromosome 21 genomic contig, reference assembly
Homo sapiens nuclear receptor subfamily 2, group F, member 1 (NR2F1), mRNA
Homo sapiens N-ethylmaleimide-sensitive factor attachment protein, alpha
Homo sapiens tubulin, beta 2A (TUBB2A), mRNA
Homo sapiens capicua homolog (Drosophila) (CIC), mRNA
Homo sapiens proline rich 7 (synaptic) (PRR7), mRNA
Homo sapiens chromosome 16 genomic contig, reference assembly
Homo sapiens high-mobility group 20A (HMG20A), mRNA
Homo sapiens chromosome 15 genomic contig, reference assembly
Homo sapiens APC11 anaphase promoting complex subunit 11 homolog (yeast)
Homo sapiens complement component 4B (Childo blood group) (C4B), mRNA
Homo sapiens chromosome 20 genomic contig, reference assembly
Homo sapiens chromosome 8 genomic contig, alternate assembly
Homo sapiens ribosomal protein L29 (RPL29), mRNA
Homo sapiens chromobox homolog 4 (Pc class homolog, Drosophila)
Homo sapiens TNFAIP3 interacting protein 2 (TNIP2), mRNA
Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA
Homo sapiens chromosome 1 genomic contig, reference assembly
Homo sapiens chromosome 1 genomic contig, reference assembly
Homo sapiens surfeit 6 (SURF6), mRNA
Homo sapiens ribosomal protein L7a (RPL7A), mRNA
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA
Homo sapiens manic fringe homolog (Drosophila) (MFNG), mRNA
Homo sapiens chromosome 11 genomic contig, reference assembly
Homo sapiens coiled-coil domain containing 88 (CCDC88), mRNA
Homo sapiens chromosome 13 genomic contig, alternate assembly
Homo sapiens fusion (involved in t(12; 16) in malignant liposarcoma)
Homo sapiens hypothetical protein FLJ12949 (FLJ12949), transcript
Homo sapiens chromosome 14 genomic contig, reference assembly
Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog K (avian)
Homo sapiens splicing factor, arginine/serine-rich 10 (transformer 2 homolog,
Drosophila) (SFRS10), mRNA
Homo sapiens apolipoprotein B48 receptor (APOB48R), mRNA
Homo sapiens chromosome 2 genomic contig, reference assembly
Homo sapiens heat shock 70 kDa protein 4 (HSPA4), transcript variant 1, mRNA
Homo sapiens ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1),
Homo sapiens retinoic acid induced 1 (RAI1), mRNA
Homo sapiens chromosome 11 genomic contig, alternate assembly
Homo sapiens chromosome 1 genomic contig, reference assembly
Homo sapiens chromosome 2 genomic contig, reference assembly
Homo sapiens chromosome 2 genomic contig, reference assembly
Homo sapiens centrosomal protein 250 kDa (CEP250), transcript variant 2, mRNA
Homo sapiens chromosome 17 genomic contig, reference assembly
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens pre-B-cell leukemia transcription factor interacting protein 1
Homo sapiens hypothetical protein FLJ12949 (FLJ12949), transcript variant 1,
Homo sapiens pre-B-cell leukemia transcription factor Interacting protein 1
Homo sapiens pre-B-cell leukemia transcription factor interacting protein 1
Homo sapiens chromosome 14 genomic contig, reference assembly
Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA
Homo sapiens hypothetical protein FLJ12949 (FLJ12949), transcript variant 1,
Homo sapiens ribosomal protein S2 (RPS2), mRNA
Homo sapiens apoptosis antagonizing transcription factor (AATF), mRNA
Homo sapiens pre-B-cell leukemia transcription factor interacting protein 1
Homo sapiens chromosome 22 genomic contig, reference assembly
Homo sapiens hypothetical protein FLJ12949 (FLJ12949), transcript variant 1,
Homo sapiens lamin A/C (LMNA), transcript variant 2, mRNA
Homo sapiens chromosome 17 genomic contig, reference assembly
Homo sapiens ankyrin repeat and sterile alpha motif domain containing 6 (ANKS6),
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens chromosome 1 genomic contig, reference assembly
Homo sapiens endothelial differentiation, sphingolipid G-protein-coupled
Homo sapiens chromosome 3 genomic contig, reference assembly
Homo sapiens chromosome 1 genomic contig, reference assembly
Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA
Homo sapiens apoptosis antagonizing transcription factor (AATF), mRNA
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens chromosome 2 genomic contig, reference assembly
Homo sapiens chromosome 11 genomic contig, reference assembly
Homo sapiens endoplasmic reticulum protein 29 (ERP29), transcript variant 2,
Homo sapiens pre-B-cell leukemia transcription factor interacting protein 1
Homo sapiens TEL2, telomere maintenance 2, homolog (S. cerevisiae)
Homo sapiens BCL2-like 12 (proline rich) (BCL2L12), transcript variant 1, mRNA
Homo sapiens myelin basic protein (MBP), transcript variant 8, mRNA
| Number | Date | Country | Kind |
|---|---|---|---|
| 102007041657.3 | Sep 2007 | DE | national |
This application is a continuation of application Ser. No. 12/676,178, filed Jun. 21, 2010, and the entire contents of which is incorporated by reference herein. Application Ser. No. 12/676,178 is a national stage application (under 35 U.S.C. §371) of PCT/DE2008/001546, filed Sep. 3, 2008, and claims the benefit of German application 102007041657.3, filed Sep. 3, 2007.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12676178 | Jun 2010 | US |
| Child | 14453340 | US |
